Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 46Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 30Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 23Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasms 15Carcinoma, Renal Cell 15Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

Rituximab 16zanubrutinib 12ibrutinib 9venetoclax 8Cyclophosphamide 8pirtobrutinib 5fludarabine phosphate 5Whole-Body Irradiation 5Sirolimus 5Mycophenolic Acid 5Bendamustine Hydrochloride 5acalabrutinib 4Peripheral Blood Stem Cell Transplantation 4Dexamethasone 4ixazomib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Cyclosporine 3Bortezomib 3Biopsy 3fludarabine 2carfilzomib 2Tacrolimus 2Prednisone 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Biopsy × 1 year × Clear all
NCT04840602 2026-06-03

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07420959 2026-02-19

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Mayo Clinic

Phase 1/2 Not yet recruiting
38 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

Phase 1 Recruiting
46 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmSarcoma

Blastic Plasmacytoid Dendritic Cell Neoplasm, Histiocytosis, Langerhans-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Erdheim-Chester Disease, Dendritic Cell Sarcoma, Interdigitating, Histiocytic Sarcoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡